Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and mortality world-wide, 1 with a lifetime risk of 2 in 3 for men and greater than 1 in 2 for women. 2 Many epidemiological studies have identified risk factors contributing to the development of CVD, and randomized clinical trials have demonstrated that lower levels of these standard risk factors are associated with a lower disease incidence. The American Heart Association (AHA) has formulated the 2020
Strategic Impact Goals for reducing the CVD burden by 20% and increasing 'cardiovascular health' by 20% by the year 2020. 3 To achieve these goals, the AHA has proposed seven healthy behaviors and factors (Life's Simple 7 TM or the AHA Cardiovascular Health score), i.e., nonsmoking status, ideal body mass index (BMI), regular physical activity, healthy diet, and an optimal profile of serum cholesterol, blood pressure, and blood glucose, all markers of an ideal cardiovascular health. 3 Recent data suggest that the AHA Cardiovascular Health score is inversely associated with the incidence of CVD. [4] [5] [6] [7] [8] [9] However, the biological mechanisms underlying this association are not entirely clear. CVD is a life-course disease that develops over decades, with subclinical atherosclerosis being a fundamental precursor. 10 Additionally, multiple biomarkers representing key biological pathways have been associated with CVD, 11 suggesting that the onset of CVD likely represents the combinatorial effect of activated biological pathways acting synergistically with the substrate of subclinical atherosclerosis. Therefore, it is likely that the protective effects of the CVH score on CVD incidence may be mediated by its favorable effects on subclinical disease and on the concentrations of CVD biomarkers. However, no prior study has examined this premise comprehensively. Accordingly, we hypothesized that a higher AHA Cardiovascular Health score is associated with: a. a more favorable biomarker profile (lower concentrations of pro-atherosclerotic, neurohormonal, and cardiac stress biomarkers and moking status, ideal body mass index (BMI), regular physical activity, healthy d d die iet, t, t a a and nd nd a a an n n optimal profile of serum cholesterol, blood pressure, and blood glucose, all markers of an ideal ca ard rd dio io iov va vasc sc cul ul ula a ar h hea ea ealt lth. 3 Recent data suggest that th th the e AHA Cardio ova va v scul ul ular ar ar Health score is n nve e ers r ely asso oci ci ia a ate ed ed w w wit th h h th th the e e in in inci cide de den nc nce e o o of C CV VD. 4--9 H How ow wev eve e er, , th the e e b bi biol olo og gi ic cal al m m mec echa ha hani ni nism sm ms s un unde de d rl rl rlyi yi ying ng ng t t thi h his s a a ass so soci ciat ati io ion n ar ar re e no no not t t e en enti ti ire re ely ly ly c c cle e ear ar a . . CV CV VD D D is is s a a a l lif f fe-e-e c co cour ur urse se s di is isea ea ase se s t t tha ha at t t d d dev v velo lo ops ps ov ve ver decades, wit th h su su subc bc cli li ini ni ica ca cal at at athe he hero o osc sc scle le ero ro r si si sis s s be be bein in ing g g a a fu fu und nd n am m men en enta ta al l pr pr prec e e ur ur urso so sor. r. r 10 10 10 A A Add dd dit it itio io iona na nall lly, multiple e e higher levels of cardio-protective biomarkers); b. a lower prevalence of subclinical CVD; and c. a lower incidence of CVD, in part mediated by the lower burden of subclinical disease and a favorable biomarker profile. We tested these hypotheses in the large community-based
Framingham Offspring Study sample.
Methods

Study sample
The study design and methods of the Framingham Heart Study have been described elsewhere 12 For the present investigation, we included Framingham Offspring cohort participants attending their sixth examination cycle (1995) (1996) (1997) (1998) , when routine assessment of subclinical disease measures was performed 13, 14 along with assays of multiple biomarkers. 11 Three samples contributed to the present investigation, corresponding to the hypotheses tested. Of 3532 attendees, participants were excluded for: prevalent CVD (n=412), serum creatinine levels 2 mg/dL (n=8), BMI <18.5 kg/m 2 (n=45), missing components of the CVH score (n=175), outlier values (n=9), and non-available concentrations of biomarkers (n=203). The remaining sample of 2680 participants was used to evaluate the association between the CVH score and each biomarker (sample 1, Supplementary Figure 1) . Additionally, 1041 participants were excluded for inadequate information regarding one or more measures of subclinical disease, yielding a sample of 1842 individuals in whom we assessed the association between the CVH score and presence of subclinical disease (sample 2, Supplementary Figure 1) . Finally, a third sample was constituted to assess the association between the CVH score and the incidence of CVD, and to evaluate whether any potential relation was mediated by the association of the CVH score with circulating biomarker levels and/or subclinical disease. We excluded 16 participants from heir sixth examination cycle (1995) (1996) (1997) (1998) , when routine assessment of subclinica ca al di di d se se eas s ase e e measures was performed 13, 14 along with assays of multiple biomarkers. 11 Three samples co ont nt ntri ri ribu bu bute te ted d d to to to the he e p p pr resent investigation, correspo o ond nd nding to the hyp pot o o he ese se es s s te t sted. Of 3532 at tte en ndees, par rti tici ci cipa ant nts s s w we were re re e e ex x xcl clud ud ude ed ed f fo or r: pr r rev v vale en nt t t CV V VD D D ( (n (n= =4 =412 12) ), s ser erum um um c cr re rea at atin inin in ine e e le l leve ve els ls ls 2 2 2
), B BMI MI MI < <1 18. .5 5 k kg/ g/ /m m 2 2 ( ( (n= n= n=45 45), ), ) m m mis is issi ing ng ng c c co om mp po pone ne nent n nts s of of o t the he he C C CVH VH VH s sc co core re re ( ( (n= n= n=17 175 5 5), , , ou out t tlie ie er r values (n=9) 9) ), , an an and d no no non-n-av av a ai ai ila la labl b b e e e co co conc nc ncen n ntr tr t at at atio io ions ns n o of f f b b bio io ioma ma ark rk rker er ers s (n (n (n=2 =2 203 03 03). ). ) T T The he he r rem em emai ai aini ni ning ng ng sample of f f f f sample 2 for non-available biomarker levels yielding a sample in which both biomarker levels and subclinical disease measures were available (n=1826, sample 3, Supplementary Figure 1) .
We formally compared clinical characteristics between the participants included in this investigation and those who were excluded for the aforementioned reasons, and there were no major differences (Supplementary Table 1 ). The study protocols were approved by the Boston University Medical Center Institutional Review Board and all participants provided written informed consent.
AHA Cardiovascular Health Score
For each participant, we constructed a cardiovascular health score by recoding the 7 metrics (Supplementary Table 2) 3 as dichotomous variables, with a score of 1 indicating the AHA ideal category for that metric (versus 0 for non-ideal metric); thus the CVH score could vary from a minimum of 0 (indicating poor cardiovascular health) to a maximum of 7 (reflecting ideal cardiovascular health). Fasting blood glucose, cholesterol, resting blood pressure and BMI, and self-reported smoking status obtained at the Heart Study clinic were used for categorizing these components of the CVH score. Dietary quality was assessed using the food frequency questionnaire administered at the examination (Supplementary Table 2 ). Physical activity was measured using a questionnaire-based physical activity index (with a value in the upper quartile indicating physically active, Supplementary Table 2) .
Subclinical Disease Measurements
At the sixth examination cycle, attendees underwent testing for several subclinical disease measures (Supplementary Table 3) . 3, 13, 14 A standard 12-lead resting electrocardiogram was obtained on study participants and the sex-specific Cornell voltage criteria were used to evaluate electrocardiographic LVH. Standardized two-dimensional transthoracic echocardiography was 
Supplementary
Circulating Biomarker Measurements
Venous blood was drawn on all attendees in the morning after an overnight fast, and biosamples were stored at -70 C until assayed. We measured circulating concentrations of 12 biomarkers representing the following distinct biological pathways: inflammation (C-reactive protein 
11, 15
Outcome events
The outcome of interest was incidence of a first CVD event during follow-up from the baseline examination, consistent with prior Framingham publications. CVD events included coronary heart disease (myocardial infarction, coronary insufficiency, and angina pectoris), stroke or transient ischemic attack, intermittent claudication or heart failure. Criteria for these CVD events have been described previously.
16
Statistical Analysis
We natural-logarithmically transformed all biomarkers to normalize their skewed distributions.
The CVH score was used as defined by the AHA strategic guidelines, using 7 components (Supplementary Table 2 
O Out tc tcome even ents ts s
Th Th he e e ou ou utc tc tcom om ome e e of of f i int nt ter ere e est t wa wa w s in in i ci ci cide de den nc nce e of of of a a a f f firs rs st t t CV CV CVD D ev ev even en ent t t du du duri ri ing ng ng f f fol ol ll l low w-w-up up up f f fro ro rom m m th the e e ba ba ase sel l line ne e examination, n, , c c con on onsi si sist st sten en nt t t wi wi ith th th p p pri ri ior or or F F Fra r r mi mi m ng ng ngha ha ham m m pu pu publ bl blic ic i at at atio io ions ns ns. . CV CV CVD D D ev ev even en ents ts ts i i inc nc n lu lu lude de ded d d co co coronary score ranged from 0 to 7, after assigning one point to each component. In all analyses, the CVH score was modeled as a continuous variable; secondary analyses modeled the score as a categorical variable (3 categories, grouped as 0-2, 3-4, and 5-7). Subclinical disease was defined using a validated index consisting of at least one of the following (Supplementary Table 3 First, we evaluated the cross-sectional association between the CVH score and each biomarker in separate age-, sex-adjusted models using sample 1. We then assessed prospectively the association between the CVH score and the incidence of CVD in models adjusting for age, sex, and the biomarkers that were associated with the CVH score cross-sectionally in the previous step, using Cox proportional hazards regression models after confirming that the assumption of proportionality of hazards was met. The objective of this step was to evaluate whether the addition of the biomarkers attenuate the Hazard Ratio associated with CVH score adjusting for age and sex.
Next, we evaluated the cross-sectional association between the CVH score and the presence of subclinical disease in age-, and sex-adjusted logistic regression models using sample 2; the use of logistic regression models allowed the comparison between outcomes defined by various numbers of subclinical disease components (i.e., 1 vs. 0, 2 vs. 0 or1 and 3 vs. 0,1, or 2).
Finally, we examined prospectively in sample 3 (individuals in this sample had measurements of both subclinical disease and biomarkers) the association of the CVH score with CVD incidence adjusting for age, sex, subclinical disease and the biomarkers associated with he association between the CVH score and the incidence of CVD in models adj ju u usti ti ing ng g f f for or or a a age ge g , , ex, and the biomarkers that were associated with the CVH score cross-sectionally in the pr rev ev vio io iou us us s s ste te tep, p, usi si sin ng ng Cox proportional hazards re e egr g g e e ession models af a a ter r co co conf n irming that the assu u ump m tion of f pr pr rop p por orti ti t on on nal al alit it ity y y of of h h haz az zar ar rd ds s wa a as met t t. T The e e o ob obje je ec ct tiv ive e e o of of t thi hi his st step ep p w w was as t t to o ev eval alu ua uate te e wh wh het et ethe he her r th the e e ad a addi di it tio on on o o of th th t e e bi bi biom om mar ar arke ke k rs rs s a a att tt tten en enua ua ate te t t t the he e H H Haz az zar ar ard d d R Ra Rati ti io o as as asso so oci i iat ated ed ed w w wit ith h h CV CV CVH H H sc sco or ore e adjusting for r ag ag age e e an an and d d se se sex. x CVD incidence in step 2 (see above), using Cox proportional hazards regression. Subclinical disease was included in the models as an ordinal variable, with values 0-5, based on the number of components present.
Although the CVH score is not created for risk prediction, we performed exploratory analyses evaluating the performance characteristics of all models to assess the incremental contribution of biomarkers and subclinical disease to the CVH score for predicting CVD incidence, using 18, 19 : the increment in the C-statistic (data not shown). A 2-sided value of P<0.05 was considered statistically significant. All analyses were performed using SAS software version 9.3. (Cary, NC). The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written. Table 1 summarizes the baseline characteristics of sample 1 (the largest sample). Approximately 30% of participants had a CVH score between 0 and 2, about 52% between 3 and 4, and the remaining 18% between 5 and 7. The distributions were similar in samples 2 and 3 Tables 4 and 5 ). These data suggest an overall low prevalence of ideal cardiovascular health by the CVH score, consistent with what has been reported for middle-age to older white individuals in the United States.
Results
(Supplementary
In age-and sex-adjusted models, circulating NT-proANP and B-type natriuretic peptide concentrations were directly and linearly associated with the CVH score, whereas plasminogen activator inhibitor-1, aldosterone, C-reactive protein, D-dimer, fibrinogen, homocysteine, and growth differentiation factor-15 concentrations were inversely related to the CVH score (p<0.001
for all, Table 2 ). These associations remained robust regardless of the presence of BMI as a ntegrity. All authors have read and agree to the manuscript as written.
Re Resu su sult lt lts s s T Tab bl ble 1 summa mar ri r z zes s th th t e e e ba ba base se eli li line ne c c ch ha har ra ac ct teris is sti ics o o of f s samp mp mple le 1 ( (th the e e l la arg rge es st sa amp mp mple le). ). A A App pp p ro ro r xi xi xim m mat t tely 30 0 0% % % of of of p p par ar rti ti tici c cipa pa ant nt ts s ha ha ad d a a CV CV VH H H sc sc scor or ore e be be betw tw twe e een n n 0 0 0 a a an nd d 2 2 2, , ab ab abo ou out t t 52 52 5 % % be be b tw tw we ee een n 3 3 3 an an a d d d 4, 4 4, an nd nd t the he emaining 18 8% % % be be etw tw twee ee en n n 5 an an and d d 7. 7. 7. T The he h d d dis is i tr tr trib ib bu u uti ti tion on ons s s we we w re re e s sim im imil il i ar ar ar i i in n sa sa samp mp mple le les s s 2 2 an an and d d 3 3 3 covariate in the statistical models. Supplementary Figure 2 displays the distribution of each biomarker in relation to the CVH score. Adjusting for age, sex, and select biomarkers, the CVH score was significantly inversely associated with the incidence of CVD (p<0.001). From the panel of 9 biomarkers that were cross-sectionally associated with the CVH score, GDF-15, BNP and PAI-1 were retained in the statistical model for CVD incidence, additionally adjusting for age and sex (HRs, 1.617, 1.143, and 1.388 per 1-unit increment in log-GDF-15, log-BNP, and log-PAI-1, respectively).
We also observed a statistically significant association between the CVH score and subclinical disease in cross-sectional analyses (p<0.0001, Table 3 ), with a higher CVH score being associated with lower odds of subclinical disease; this relationship is also graphically depicted in Figure 1a , where a pattern of decreasing odds of subclinical disease is evident as the CVH score increases. Finally, in prospective analyses, the CVH score was inversely associated with the incidence of CVD in age-and sex-adjusted models in the combined sample (267 CVD events [150 coronary heart disease, 36 congestive heart failure, 22 intermittent claudication, and 59 cerebrovascular disease events] over a maximum follow-up period of 16 years; sample 3; Table 4 ). This inverse association remained statistically significant upon additional adjustment for significant biomarkers associated with the incidence of CVD (i.e., PAI-1, BNP and GDF-15) and, after additional adjustment for the presence of subclinical disease) (p=0.012, Table 4 ). The effect of the mediation of the association between the CVH score and CVD incidence is reflected by a 50% decrease in the parameter estimate for the CVH score comparing models with and without the biomarkers, and a further 50% decrease in the parameter estimate for the CVH score comparing models with and without the subclinical disease (both including the biomarkers). Table 6 ).
In secondary analyses, we also created an additional CVH score, using 3 levels for each component (0 = poor status, 1 = intermediate status, and 2 = ideal status), thus yielding a CVH score ranging from 0 to 14 for each participant. We performed the same analytical steps as described in the Methods Section for the CVH score, and results were essentially similar (see
Supplementary Tables 7-10)
Discussion
Principal findings
First, our investigation showed a low prevalence of ideal cardiovascular health in our middleaged white sample, consistent with prior reports. Second, the CVH score was directly associated with higher circulating concentrations of natriuretic peptides but inversely related to blood levels of other markers. Third, the CVH score was inversely associated with the presence of subclinical disease. Fourth, a higher CVH score was associated with a lower risk of CVD. The demonstration of a temporal sequence (CVH score antedated CVD incidence), the strength of the In secondary analyses, we also created an additional CVH score, using 3 3 le l leve v v ls ls s f f for or or e e eac ac a h h component (0 = poor status, 1 = intermediate status, and 2 = ideal status), thus yielding a CVH c cor or re e e ra ra rang ng gin in ing g g fr rom om om 0 0 to 14 for each participant. W W We e performed th he e e same me me a analytical steps as d de desc c cri r bed in the he M M Met tho ho h ds ds ds S S Sec ec cti ti tion on f f fo or or t the he e CVH VH VH sco or ore e, a a an nd nd r re es esul ults ts s w w wer ere e es esse sen nt ntia ia iall lly y si si imi mi mila l l r r r ( (s (se e ee Su Supp pp pple le leme ment nt ntar ary y y T Ta Tabl bl les es 7 7-1 -0 0 0) ) ) association, the presence of a dose-response, the consistency in multiple analyses, and the biological plausibility of the relationship make it likely that the observed association is a causal one. Additionally, the association between the CVH score and the incidence of CVD was only partly mediated (in an epidemiological sense) by subclinical disease and select biomarkers, which suggests that our primary hypothesis was not proven. We could not fully account for the benefits of ideal cardiovascular health, suggesting that the tested biomarkers and subclinical disease measures incompletely explain ideal cardiovascular health. We did not adjust for physical fitness and CAC (2 powerful markers of CVD), which could contribute to the association between ideal CVH and CVD and explain this potential "gap". Additionally, residual
confounding may be present due to modeling select exposures as binary variables.
Comparison with the published literature
Several studies have reported a low prevalence of ideal cardiovascular health in the United
States. 4-6, 9, 20-22 Our findings are consistent with the observed low prevalence rates of ideal cardiovascular health overall among whites in the United States. Other studies have shown that a higher CVH score is inversely associated with the incidence of CVD. [4] [5] [6] [7] [8] [9] Our observations confirm these findings and also validate the linear association between the CVH score and incidence of CVD, thereby establishing the CVH score as a reasonable goal/target for public health efforts.
The association of the CVH score with CVD incidence is somewhat intuitive, given that premier risk factors and key lifestyle factors constitute the score per se. Yet, few studies have investigated the impact of the CVH score on potential mediators of the association, i.e., CVD biomarkers and or/subclinical atherosclerosis/target organ damage. The Special Turku Coronary Risk Factor Intervention Project (STRIP) for Children study evaluated adolescents and reported that a healthy CVH score was associated with lower aortic intimal-medial thickness and greater confounding may be present due to modeling se lect exposures as binary variables es s.
Comparison with the published literature
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4-6, 9, 2 20-2 0-22 2 O O Ou u ur f f fin in i di di ding ng ngs s s a ar are e co co con ns nsi is st te ent w w wi i ith th h he e e ob b bse se erv rved ed d l low ow w p pre rev v val le enc nc ce e ra rate te es s s of of of i i ide e eal a al ca ard rd rdio io iova va v sc scul ul ular ar h hea ea alt lth h ov ov ver eral ll l l am am mon on ong g g w wh whit it ites es es in n n th th t e e e U U Uni it ited ed d S S Sta tate te tes. s. O O Ot t the he h r r r st st tud ud die ie i s s s ha ha ave ve ve sh h how wn wn t t tha a at t a higher CVH s s sco co core re e i is s s in in nve v v rs rs sel el ely y y as as asso so s ci ci c at t ted ed ed w w wit it i h h h th th the e e in in inci c de de denc nc nce e e of of of C C CVD VD VD. . elasticity. 23 In the Cardiovascular Risk in Young Finns study, a favorable cardiovascular health in childhood was associated with a lower carotid-intimal thickness in young adulthood. 24 In the present investigation, we demonstrate the association of the CVH score with a panel of CVD biomarkers that represent distinct biological pathways. These observations are consistent with the likely pleiotropic effects of the CVH score components on a range of biological pathways. Of interest and unexpectedly, a high CVH score was associated with higher concentrations of natriuretic peptides, which are often triggered by hemodynamic stressors such as high blood pressure; of note, the circulating natriuretic peptide levels in our sample were within the normal range, not indicative of disease. However, natriuretic peptides are also inversely associated with obesity 25 and directly related to female sex. It is likely that a lower BMI and excess of women in the higher CVH score range explain the direct association of the score with blood natriuretic peptide levels. It is noteworthy that these associations were maintained with and without adjustment for BMI. We also demonstrate a linear inverse association between an increasing CVH score and subclinical disease using a previously validated index that is a composite of subclinical atherosclerosis in several key vascular territories and the presence of target organ damage. It should be noted that the most common forms of subclinical cardiovascular disease are carotid IMT abnormalities and presence of microalbuminuria; echocardiographic left ventricular systolic dysfunction and reduced anklebrachial index are uncommon in our sample. Furthermore, we demonstrate that the CVH score is associated with CVD risk beyond its association with key CVD biomarkers and subclinical disease (as evidenced by the robust association with CVD incidence even upon adjustment for the latter two sets of variables). Thus, it is likely that other biological mechanisms may play a role in mediating the association of the CVH score with CVD risk. Additional studies are nversely associated with obesity 25 and directly related to female sex. It is likely y t th that at a a a l l low ow ower er er BMI and excess of women in the higher CVH score range explain the direct association of the c cor or re e e wi wi with th th b b blo lo lood d d n n nat atriuretic peptide levels. It is n n not ote eworthy that t the he h se a a ass ss ssoc o iations were m mai in intained wit ith h h an n nd d w wi w th th thou ou o t t t ad a adju just st s m me ment nt t for r B B BMI. . W W We al al lso so de em emo on onst stra rate te a a a l lin in ne ea ear r in in nve ve ers rse e as sso so soci ci ciat at a io ion n n be be betw twee e en n an an i i inc ncre ea as a in in ing g g CV CV C H H H sc sc sco or ore e an an a d d d s su sub bc bcli li ini ni nica cal l l di di d se se s as as ase e u u usi in ing g a a a pr pr prev ev vio io ious s sly ly validated inde de ex x x th th hat at at i is s s a a a co o omp mp mpos s sit it ite e of of o s s sub ub ubcl cl clin in inic ic ical al al a a ath th ther e os os oscl cl cler er eros os sis is is in n n se se seve ve vera ra ral l l ke ke k y y y va va vasc sc scul ul u ar warranted to evaluate serial changes in the CVH score in individuals and the association of such changes in the CVH score with CVD incidence. It should also be noted that greater physical fitness may be an important mediator of the inverse relationship between the CVH score and CVD; however, data on physical fitness were not available in our sample at this examination cycle. As a final note, Ahmed et al 26 reported an association between regular exercise, nonsmoking status, healthy diet, and weight maintenance with lower values of coronary artery calcium incidence, slower progression of calcium and also lower all-cause mortality; the importance of this investigation lies in the fact that the authors used only lifestyle factors (thereby focusing more on habits and not on risk factors that evolve downstream), as compared to the CVH score that combines lifestyle and biochemical factors).
Strengths and Limitations
The present investigation included a large community-based sample, with an available comprehensive panel of CVD biomarkers and a validated group of subclinical disease measures, and combined cross-sectional and longitudinal analyses. Some limitations of the present study should be acknowledged. We did not use coronary artery calcification for the definition of subclinical disease, because measurements were not available at the sixth examination cycle of the Framingham Offspring cohort. The CVH score, biomarker panel and subclinical disease were all assessed at a single examination; such single occasion measurements are prone to regression dilution bias and we may have underestimated the true strength of the association of the CVH score with CVD risk. Moreover, the generalizability of our study findings is limited to white middle-aged to older participants of European ancestry. Additionally, we did not relate the individual components of the CVH score with the outcomes, but rather chose to analyze it as a composite consistent with its intended use. Finally, diet and physical activity were defined using o the CVH score that combines lifestyle and biochemical factors).
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Conclusions
In our large community based sample, an ideal cardiovascular health measured by the CVH score was associated with a favorable profile of circulating CVD biomarkers, and with a lower prevalence of subclinical disease. Additionally, the incidence of CVD was inversely and linearly related to the CVH score, an association that was partly mediated by the relation between the CVH score and circulating CVD biomarkers and subclinical disease. Additional studies are warranted to confirm our results and to evaluate other cardio-protective mechanisms associated with the CVH score. Overall, while our findings are observational, they are consistent with the notion that improving the cardiovascular health (with the CVH score as a metric) of the public with an advocacy for better lifestyle habits and a more favorable CVD risk factor profile may translate into a lower incidence of CVD in the long-term, perhaps in part by favorable influences on key CVD biomarkers as well as on the burden of subclinical atherosclerosis and target organ damage. Values are betas (95% CI) and p values. Each beta coefficient represents the change in log-biomarker per 1-unit increase in the CVH score (i.e. e -fold increase in biomarker. For example, a 1-unit increase in the CVH score corresponds to a decrease of 0.038 units in log-aldosterone, which corresponds to an e -0.036 = 0.965-fold increase in aldosterone). Table 3 . Age-sex-adjusted cross-sectional associations between CVH score (per 1-unit increase) and subclinical disease. Table 4 . Association of CVH score (per 1-unit increase) with the incidence of CVD: impact of adjustment for biomarkers and subclinical disease. Table 4 . Clinical characteristics of sample used for assessing the association between the CVH score and presence of subclinical disease. Table 5 . Clinical characteristics of sample used for assessing the prospective association between the CVH score and incidence of cardiovascular disease. 
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